NCT02197728

Brief Summary

We hypothesize, that the use of the Hohl manipulator® at total laparoscopic hysterectomy reduces operative time (from skin incision to detachment of the uterus) and lateral termal damage of the vaginal wall during colpotomy due to the following reasons: (1) Uterine manipulation is better with the Hohl manipulator®, thereby facilitating dissection during all aspects of the surgery, (2) more tension can be applied on the vagina during colpotomy, thereby hastening electrosurgical transection, reducing activation time and reduce lateral thermal damage and (3) tension on the vagina can be applied until the colpotomy is finished, due to the tight connection between the Hohl manipulator® and the cervix of the uterus, which also affects speed of transection, electrosurgical device activation time and lateral thermal damage.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
91

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2014

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 23, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 23, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

February 22, 2019

Status Verified

February 1, 2019

Enrollment Period

1.8 years

First QC Date

May 23, 2014

Last Update Submit

February 20, 2019

Conditions

Keywords

hysterectomy, uterine manipulator, thermal damage, laparoscopy, colpotomy

Outcome Measures

Primary Outcomes (3)

  • Detachment of the uterus

    Operative time from skin incision to detachment of uterus. Times are routinely collected by operating room nursing staff.

    45 minutes to 3 hours

  • Thermal Damage

    Lateral thermal damage to the vagina will be measured on the specimen (in mm) at the time of pathologic evaluation.

    2 weeks post surgery

  • Colpotomy

    Time from first monopolar energy activation to completion of colpotomy. Operative times are routinely collected by operating room nursing staff.

    3 minutes to 20 minutes

Secondary Outcomes (3)

  • Blood Loss

    45 minutes to 3 hours

  • Pain

    24h post surgery

  • Manipulator Installment

    intraoperative

Study Arms (2)

Hohl uterine manipulator ®

ACTIVE COMPARATOR

Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®

Device: Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy

Colpo-Probe™ Vaginal Fornix Delineator

ACTIVE COMPARATOR

Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator

Device: Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy

Interventions

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All women aged over 18 years, scheduled for a laparoscopic hysterectomy for a benign disorder will be asked to participate and included after written informed consent.

You may not qualify if:

  • pregnancy
  • malignancy
  • if uterine size exceeds 20 weeks of gestation
  • or if the uterus could be removed by a vaginal approach

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Michael´s Hospital

Toronto, Ontario, M5B 1W8, Canada

Location

Study Officials

  • Guylaine Lefebvre, MD

    Unity Health Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 23, 2014

First Posted

July 23, 2014

Study Start

February 1, 2014

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

February 22, 2019

Record last verified: 2019-02

Locations